Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889944 | 0.81 | CYP2D6 (0.35) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL8455009 | 0.80 | KEAP1 (0.40) | KEAP1NFE2L2HDAC3HDAC1HDAC2 | |
| SCHEMBL544155 | 0.76 | — | — | |
| SCHEMBL10512876 | 0.75 | DGAT1 (0.36) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL14945698 | 0.73 | DGAT1 (0.34) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL2042195 | 0.72 | — | — | |
| SCHEMBL1186917 | 0.72 | — | — | |
| SCHEMBL6894335 | 0.72 | KEAP1 (0.36) | KEAP1NFE2L2 | |
| SCHEMBL12033651 | 0.71 | DGAT1 (0.33) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL17643549 | 0.71 | CYP2D6 (0.37) | CYP2D6DGAT1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| WO-2008086854-A1 | 5-([1,3,4] OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4] THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-4576749-A | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0138407-A1 | Azetidinones | E.R. Squibb & Sons, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | SGK2, SGK1, SGK3 | KEAP1 797/4885NFE2L2 2203/4885CYP2D6 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.